Riskpilot← Back to searchSign inGet full accessNORSE FUND AS
ASIn liquidationOrg 889086092Buying and selling of own real estate · NACE 6811Est. 20050 employees
Revenue 2025
NOK 0
EBITDA margin
—
-695% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
NOK 128K
+30574% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -8K | -695% |
| Net profit | NOK 128K | +30574% |
| Total assets | NOK 216K | +170% |
| Equity | NOK 216K | +144% |
| Employees | 0 | — |
Legal name
NORSE FUND AS
Org number
889086092
Legal form
Aksjeselskap
NACE code
6811 · Buying and selling of own real estate
Founded
22. desember 2005
Share capital
NOK 90 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Investering i eiendom og andre selskaper samt det som naturlig hører hertil.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 50 | 0 | 0 | 0 | 0 |
| Staff expenses | −53 | −0 | −0 | −0 | −0 |
| EBITDA | −15 | 0 | −0 | −1 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −15 | 0 | −0 | −1 | −8 |
| Net financials | 0 | 0 | 0 | 1 | 136 |
| Profit before tax | −15 | 0 | −0 | −0 | 128 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −15 | 0 | −0 | −0 | 128 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 89 | 89 | 89 | 80 | 216 |
| Equity | 89 | 89 | 89 | 88 | 216 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | −8 | 0 |
| Total debt | 0 | 0 | 0 | −8 | 0 |
EBITDA margin
-841400.0%
This company
15.8%
Market median
-5325416% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
59.1%
This company
18.4%
Market median
+221% vs market
20212025
Net profit margin
12768700.0%
This company
8.1%
Market median
+157638172% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
VP Deputy Member | Deputy Member | 2005 |
AE Chief Executive Officer | Chief Executive Officer | 2005 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NORSE FUND AS 
UNI PHARMA HOLDING ASBoard members of NORSE FUND AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vigdis Petra Hagen Wold | Deputy Member | 0 companies |
| Alf Egil Hagen | Chief Executive Officer | 0 companies |